Covid-19 roundup: Moderna adds vaccine experts as PhIII trial looms; Feng Zhang group snags instant OK on CRISPR-based test
Moderna has expanded its top executive team as it confirms its timeline on a hectic race to the finish line for one of the leading vaccines now in the clinic for Covid-19. And CEO Stéphane Bancel raided some prominent biopharmas for more vaccine talent — both in commercial as well as development ops — even as he starts a hunt for a new CFO as Lorence Kim hits the exit after 6 years with the Boston-based upstart.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,800+ biopharma pros reading Endpoints daily — and it's free.